Osimertinib Mesylate Powder

Product Details

Osimertinib mesylate powder is the first third-generation targeted drug for lung cancer approved in China. This drug has brought new hope to the majority of lung cancer patients, and has also helped many patients improve their quality of life and prolong their survival time. , so it is very popular in the market.

Osimertinib mesylate is a targeted drug for lung cancer. It is a kinase inhibitor of the epidermal growth factor receptor EGFR, and the concentration of irreversible binding to some mutants of EGFR is about 9 times lower than that of the wild type. Osimertinib has anti-tumor effect on non-small cell lung cancer cell lines carrying EGFR mutations, and has weak anti-tumor activity against wild-type EGFR gene amplification. At clinical concentrations, osimertinib inhibits the activity of HER2, HER3, HER4, ACK1 and BLK.

Health Benefits

Indicated for locally advanced or metastatic non-small cell lung cancer with disease progression during or after prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and confirmed by testing to be positive for EGFR T790M mutation (NSCLC) for the treatment of adult patients.

Osimertinib mesylate powder is an epidermal growth factor receptor (EGFR) kinase inhibitor, and in patients with lung cancer treated with the first-generation targeted drugs erlotinib and gefitinib (Iressa), patients with drug resistance The main reason is the T790M mutation. Osimertinib can be combined with mutated EGFR genes (such as T790M, L858R and exon 19 deletions). After the patient takes the drug, two substances can be found in the blood of the patient, namely AZ7550 and AZ5104. The former is similar to the treatment effect of AZD9291, and the latter The patients with exon 19 deletion, AZ7550 mutant and wild-type EGFR showed better efficacy. In vitro test results show that AZD9291 can also inhibit the activities of HER2, HER3, HER4, ACK1, and BLK.